01.07.26 -- CSL's HEMGENIX Shows A New Future For Gene Therapy In Hemophilia B

Stem cell therapy has already revolutionized the field of oncology. But where do we go from here? Dr. Robert S. Negrin addresses three key areas of CAR T-cell therapy on the brink of innovation.

Achieve highly consistent and precise AAV vector genome titer measurements with this optimized ddPCR protocol. This method ensures accurate dosing and optimal cell therapy potency.

Public genomic datasets like TCGA transformed cancer research, guiding assay validation and cohort design. Today, matched biospecimens complete the loop between digital insight and biological confirmation.

New alternative phosphitylating reagents reduce the safety hazards associated with BCDP, enabling a safer and effective synthesis of key 5' -terminal phosphate oligonucleotide sequences.

See how total protein staining offers a robust approach to western blot normalization to minimize variability and improve quantification accuracy, which supports reproducible protein expression.

Discover the future of in vitro modeling at the Queen Mary+Emulate Organs-on-Chips Centre and unlock new possibilities in the field of predictive medicine.

Watch how to optimize iPSC culture conditions; transitioning to 3D stirred-tank bioreactors enables precise parameter control while maintaining high viability and essential stem cell characteristics.

Innovative non-viral delivery methods are revolutionizing gene therapy by enabling precise, scalable genome editing in primary cells to address a wide spectrum of complex genetic disorders.

Patient-derived organoids are revolutionizing drug discovery by mimicking tumors to predict therapeutic efficacy. Uncover a scalable, reproducible, and cost-effective bioprocess that can pave the way for broader adoption.